Sustained release tablet containing hydrocolloid and cellulose ether

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 6416786
SERIAL NO

09459300

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention is directed to a solid sustained release pharmaceutical tablet for administering to a host, comprising a therapeutically effective amount of a pharmaceutically active ingredient and a sustained release carrier therefor, said sustained release carrier comprising (a) a hydrocolloid selected from the group consisting of xanthan gum, guar gum, and alginic acid or a pharmaceutically acceptable salt thereof, and (b) a cellulose ether, said hydrocolloid and cellulose ether being present in synergistic effective amounts to retard release of said pharmaceutically active ingredient, said hydrocolloid being present in amount ranging from about 0.3% to about 7.0% by weight of the tablet and said cellulose ether being present in an amount ranging from 3% to about 20% of said tablet, and said cellulose ether being present in said carrier in amounts equal to or greater than 33% by weight and said carrier being present in amounts less than 35% by weight of said tablet.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
Nostrum Pharmaceuticals, Inc.PRINCETON, NJ10

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Inamdar, Kavita Mumbai, IN 3 7
Mulye, Nirmal Long Beach, NY 27 314

Cited Art Landscape

Patent Info (Count) # Cites Year
 
PHARMACIA & UPJOHN AB (1)
5804217 Manufacturing matrices 2 1995
 
Other [Check patent profile for assignment information] (3)
4775535 Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics 22 1986
4832956 Disintegrating tablet and process for its preparation 53 1987
4855143 Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics 22 1988
 
EURAND INTERNATIONAL S.P.A. (1)
* 5047248 Formulation for preparing sustained release drugs for oral administration 31 1989
 
ALZA CORPORATION (2)
5006346 Delivery system 32 1989
5338550 Stereoisomer therapy 8 1992
 
PENWEST PHARMACEUTICALS CO. (14)
4994276 Directly compressible sustained release excipient 72 1988
5128143 Sustained release excipient and tablet formulation 66 1990
5135757 Compressible sustained release solid dosage forms 48 1991
* 5169639 Controlled release verapamil tablets 34 1991
5472711 Agglomerated hydrophilic complexes with multi-phasic release characteristics 47 1992
5478574 Agglomerated hydrophilic complexes with multi-phasic release characteristics 28 1993
5612053 Controlled release insufflation carrier for medicaments 99 1995
5512297 Sustained release heterodisperse hydrogel systems for insoluble drugs 33 1995
5554387 Sustained release heterodisperse hydrogel systems for insoluble drugs 29 1995
5773025 Sustained release heterodisperse hydrogel systems--amorphous drugs 70 1996
5667801 Sustained release heterodisperse hydrogel systems for insoluble drugs 21 1996
5670168 Agglomerated hydrophilic complexes with multi-phasic release characteristics 29 1996
5738865 Controlled release insufflation carrier for medicaments 121 1996
5846563 Sustained release heterodisperse hydrogel systems for insoluble drugs 24 1997
 
ADVANCED TECHNOLOGY PHARMACEUTICALS CORP. (2)
5292534 Sustained release composition and method utilizing xanthan gum and an active ingredient 34 1992
5427799 Sustained release composition and method utilizing xanthan gum and an active ingredient 25 1993
 
EURO-CELTIQUE S.A. (1)
5811126 Controlled release matrix for pharmaceuticals 143 1995
 
ANDA SR PHARMACEUTICALS ICN. (1)
5419917 Controlled release hydrogel formulation 42 1994
 
GATX VENTURES, INC. (1)
5582837 Alkyl-substituted cellulose-based sustained-release oral drug dosage forms 123 1995
 
FUJISAWA PHARMACEUTICAL CO., LTD. (1)
4695467 Sustained release tablet 57 1985
 
THE DOW CHEMICAL COMPANY (2)
4734285 Sustained release compositions 41 1985
4704285 Sustained release compositions comprising hydroxypropyl cellulose ethers 66 1985
 
BEND RESEARCH, INC. (1)
5876752 Use of interfacially-polymerized membranes in delivery devices 15 1993
 
Ethical Pharmaceuticals Limited (1)
4880830 Slow release formulation 48 1987
 
PAUL ROYALTY FUND, L.P. (2)
5464633 Pharmaceutical tablets releasing the active substance after a definite period of time 84 1994
5780057 Pharmaceutical tablet characterized by a showing high volume increase when coming into contact with biological fluids 84 1997
 
ENDO PHARMACEUTICALS INC. (2)
5455046 Sustained release heterodisperse hydrogel systems for insoluble drugs 58 1993
5662933 Controlled release formulation (albuterol) 37 1995
 
E. R. Squibb & Sons, Inc. (2)
4610870 Controlled release formulation 112 1984
4792452 Controlled release formulation 114 1987
 
RECKITT BENCKISER HEALTHCARE (UK) LIMITED (1)
5415871 Therapeutic agents 38 1991
 
Plastic Dress-Up Co. (1)
5895663 Pseudoephedrine hydrochloride extended-release tablets 34 1997
 
BIOVAIL TECHNOLOGIES LIMITED (1)
5851555 Controlled release dosage forms containing water soluble drugs 40 1997
 
WARNER-LAMBERT COMPANY (2)
4973470 Sustained release pharmaceutical compositions 5 1989
5077051 Sustained release of active agents from bioadhesive microcapsules 36 1990
 
The Procter & Gamble Company (1)
4786518 Iron mineral supplements 35 1987
 
FOREST LABORATORIES, INC. (2)
4369172 Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose 242 1981
4795327 Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants 44 1984
 
BRITISH TECHNOLOGY GROUP LIMITED (1)
5063205 Uptake of iron by the body 5 1987
 
WYETH (1)
4966768 Sustained release etodolac 30 1988
 
SHIN-ETSU CHEMICAL CO., LTD. (1)
5372998 Powdery material for preparing drug-coating solution 5 1993
 
FIRST NATIONAL BANK OF GRAPEVINE (1)
5002774 Sustained release pharmaceutical tablet 45 1989
 
Daewon Pharm. Co., Ltd. (1)
5700832 Antianemic agent containing iron and difructose 8 1995
 
NOVARTIS CONSUMER HEALTH, INC. (1)
4752479 Multi vitamin and mineral dietary supplement with controlled release bioavailable iron 68 1986
 
VERLA-PHARM ARZNEIMITTELFABRIK APOTHEKER H.J.V. EHRLICH GMBH & CO. KG (1)
5143732 Orally administered pharmaceutical agent for iron and magnesium substitutive therapy 3 1989
 
LABOPHARM INC. (1)
5885615 Pharmaceutical controlled release tablets containing a carrier made of cross-linked amylose and hydroxypropylmethylcellulose 14 1996
 
EGIS GYOGYSZERGYAR (1)
5543155 Diffusion-osmotic controlled drug-release pharmaceutical composition and process for preparing same 34 1994
 
Sterling Drug Inc. (1)
5223268 Low solubility drug-coated bead compositions 18 1991
 
APR APPLIED PHARMA RESEARCH SA (1)
5681583 Multilayered controlled-release oral solid pharmaceutical forms 79 1995
 
J. RETTENMAIER & SOEHNE GMBH + CO. KG (2)
5741524 Sustained-release formulations utilizing pharmaceutical excipient having improved compressibility 114 1996
5858412 Sustained release formulations utilizing pharmaceutical excipient having improved compressibility with modified microcrystalline 100 1997
 
BASF AKTIENGESELLSCHAFT (1)
5741519 The production of active substance compositions in the form of a solid solution of the active substance in a polymer matrix, and active substance compositions produced by this process 44 1996
 
ZYMA SA (1)
4882169 Swellable pellets 31 1988
 
TCF NATIONAL BANK (1)
5126145 Controlled release tablet containing water soluble medicament 137 1990
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
Other [Check patent profile for assignment information] (2)
* 2009/0317,487 KITS FOR PREVENTION AND TREATMENT OF RHINITIS 1 2009
* 2010/0041,759 MULTI-PHASE RELEASE POTASSIUM GUAIACOLSULFONATE COMPOSITIONS 1 2009
 
AMERICAN CAPITAL, LTD. (2)
* 2010/0159,001 Extended-Release Pharmaceutical Formulations 6 2008
* 2010/0160,363 EXTENDED-RELEASE PHARMACEUTICAL FORMULATIONS 6 2009
 
MYLAN PHARMACEUTICALS, INC. (1)
* 2005/0202,079 Novel orally administrable formulation of nitrofurantoin and a method for preparing said formulation 5 2004
 
ETHYPHARM (2)
8029825 Low-dose tablets having a network of polymers 0 2004
* 2008/0031,946 Low-Dose Tablets Having a Network of Polymers 0 2004
 
TRANSFORM PHARMACEUTICALS, INC. (1)
* 2004/0106,098 Analysis of pharmaceutical solubility and stability 14 2003
 
HANMI PHARM. CO., LTD. (2)
* 7704526 Sustained release composition for oral administration of drugs 2 2003
* 2004/0081,693 Sustained release composition for oral administration of drugs 2 2003
 
VIRUN, INC. (7)
8765661 Compositions containing non-polar compounds 3 2009
8282977 Compositions containing non-polar compounds 6 2009
* 2009/0297,665 Compositions containing non-polar compounds 13 2009
* 2009/0297,491 Compositions containing non-polar compounds 7 2009
9320295 Compositions containing non-polar compounds 0 2011
* 2011/0236,364 Compositions containing non-polar compounds 7 2011
9351517 Formulations of water-soluble derivatives of vitamin E and compositions containing same 0 2014
 
Auriga Laboratories, Inc. (2)
* 2007/0141,147 SEQUENTIAL RELEASE PHARMACEUTICAL FORMULATIONS 18 2006
* 2008/0064,694 Multi-Phase Release Methscopolamine Compositions 10 2007
 
BASF AKTIENGESELLSCHAFT (1)
* 6638619 Method for producing a granulate from a melt 1 2002
 
AUROBINDO PHARMA LTD (1)
* 2009/0202,633 Extended release formulations of guaifenesin 0 2009
 
Nostrum Pharmaceuticals, Inc. (2)
* 2004/0224,017 Process for preparing sustained release tablets 37 2004
* 2011/0071,137 PROCESS FOR PREPARING SUSTAINED RELEASE TABLETS 0 2010
* Cited By Examiner